Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Hepalink

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$29M
Portfolio companies 5
Rounds per year 0.26
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 3
Key employees Soon

Areas of investment

  • Biotechnology
  • Biopharma
  • Health Care
  • Therapeutics
  • Drug Discovery
Summary

In 1998 was created Hepalink, which is appeared as Corporate Investor. The venture was found in Asia in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Hepalink, startups are often financed by Wellcome Trust, TVM Capital, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Woodford Investment Management, Wellcome Trust, TVM Capital. In the next rounds fund is usually obtained by Xeraya Capital, Bill & Melinda Gates Foundation, Bain Capital Life Sciences.

Considering the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2015.

The fund has specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Rapid Micro Biosystems, OncoQuest. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - Canada.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Hepalink:
Typical Co-investors
Hepalink is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Hepalink:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accelerator Fund Pennsylvania, Pittsburgh, United States
Ascletis Chapel Hill, North Carolina, United States
Boldcap Ventures New York, New York, United States
Bsquare Bellevue, United States, Washington
Chinese Consortium China, Jiangsu, Suzhou
CNN Atlanta, Georgia, United States
Emerald Development Managers New York, New York, United States
FastForward Area A, Palestinian Territory, West Bank
Franklin Capital Corporation Salt Lake City, United States, Utah
Fuli Capital China, Futian, Guangdong
Guangzhou Lianka Yueyuan Fazhan Youxian Gongsi China, Guangdong Province, Huangpu District
H2 Investment Properties California, San Francisco, United States
Infcurion Group Chiyoda, Japan
Locojoy Beijing, Beijing, China
Lowe's Innovation Labs Bengaluru, India, Karnataka
Nex Cubed Digital Health California, San Diego, United States
OneLiberty Ventures Cambridge, Massachusetts, United States
Prime Block Capital -
The March Fund China, Hong Kong, Hong Kong Island
Weimob China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Kymab

Biopharma
Biotechnology
Drug Discovery
Pharmaceuticals
Therapeutics
$100M24 Nov 2016 England

Rapid Micro Biosystems

Biotechnology
Manufacturing
Pharmaceutical
$25M29 Apr 2015 Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hepalink?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 6
Average round size 29M
Rounds per year 0.26
Peak activity year 2015
Lead investments 0
Follow on index 0.17
Exits 3
Group Appearance index 0.50

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Kymab

Biopharma
Biotechnology
Drug Discovery
Pharmaceuticals
Therapeutics
$100M24 Nov 2016 England

Rapid Micro Biosystems

Biotechnology
Manufacturing
Pharmaceutical
$25M29 Apr 2015 Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: